Finanzen von MiMedx Group Inc (MDXG)MDXGMiMedx Group Inc

MiMedx Group, Inc. (MDXG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Surgical, accounting for 61.1% of total sales, equivalent to $39.30M. Another important revenue stream is Advanced Wound Care. Understanding this composition is critical for investors evaluating how MDXG navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, MiMedx Group, Inc. maintains a gross margin of 68.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -28.69%, while the net margin is -23.06%. These profitability ratios, combined with a Return on Equity (ROE) of 2.88%, provide a clear picture of how effectively MDXG converts its operational activities into shareholder value.

In the context of the broader market, MDXG competes directly with industry leaders such as CTKB and MLAB. With a market capitalization of $682.97M, it holds a significant position in the sector. When comparing efficiency, MDXG's gross margin of 68.50% stands against CTKB's 58.87% and MLAB's 64.87%. Such benchmarking helps identify whether MiMedx Group, Inc. is trading at a premium or discount relative to its financial performance.

MiMedx's revenue for Q2 2026 was $64 million, down 35.1% year-over-year, and the company reported a net income loss of $14.84 million, indicating severe profitability issues. The gross margin has also dropped to 68.5% in Q2 2026 from 81.59% in Q4 2024, reflecting declining operational efficiency.